- Home
- EMR vs MRNA Comparison
EMR vs MRNA Comparison
Compare EMR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EMR | MRNA |
|---|---|---|
| Founded | 1890 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8B | 91.2B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EMR | MRNA |
|---|---|---|
| Price | $162.17 | $262.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 30 | 23 |
| Target Price | ★ $174.82 | $138.37 |
| AVG Volume (30 Days) | 2.5M | ★ 16.5M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | 17.78 | ★ 21.77 |
| EPS | ★ 3.45 | N/A |
| Revenue | ★ $24,412,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $5.14 | $8.13 |
| Revenue Next Year | $5.50 | $16.26 |
| P/E Ratio | $49.40 | ★ N/A |
| Revenue Growth | 0.78 | ★ 4.29 |
| 52 Week Low | $122.64 | $22.28 |
| 52 Week High | $172.00 | $258.72 |
Technical Indicators
Market Signals| Indicator | EMR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 65.39 |
| Support Level | $154.30 | $45.39 |
| Resistance Level | $165.58 | N/A |
| Average True Range (ATR) | 5.39 | 23.10 |
| MACD | -0.39 | 1.95 |
| Stochastic Oscillator | 44.05 | 94.48 |
Price Performance
Historical ComparisonAbout EMR Emerson Electric Company
Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands. Emerson organizes its business into seven segments that sell a wide range of automation software, power tools, and automation hardware such as valves, gauges, and switches. In recent years, Emerson divested its climate technology and consumer businesses to become more of a pure-play industrial automation company. The automation of a factory is an enticing long-term proposition for manufacturers, helping reduce accident rates and raise uptime and productivity.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.